-
1
-
-
33750949065
-
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group
-
Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997
-
(2006)
J Clin Oncol
, vol.24
, pp. 4991-4997
-
-
Van Cutsem, E.1
Moiseyenko, V.M.2
Tjulandin, S.3
-
2
-
-
41149154862
-
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie
-
Al-Batran SE, Hartmann JT, Probst S et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26: 1435-1442
-
(2008)
J Clin Oncol
, vol.26
, pp. 1435-1442
-
-
Al-Batran, S.E.1
Hartmann, J.T.2
Probst, S.3
-
3
-
-
84876951761
-
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
-
Lordick F, Kang YK, Chung HC et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 490-499
-
(2013)
Lancet Oncol
, vol.14
, pp. 490-499
-
-
Lordick, F.1
Kang, Y.K.2
Chung, H.C.3
-
4
-
-
84940594027
-
MetGastric: phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study
-
Cunningham D, Tebbutt NC, Davidenko I et al. MetGastric: phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol 2015; 33(suppl): abstr 4000
-
(2015)
J Clin Oncol
, vol.33
-
-
Cunningham, D.1
Tebbutt, N.C.2
Davidenko, I.3
-
5
-
-
84908139963
-
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
-
Wilke H, Muro K, Van Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15: 1224-1235
-
(2014)
Lancet Oncol
, vol.15
, pp. 1224-1235
-
-
Wilke, H.1
Muro, K.2
Van Cutsem, E.3
-
6
-
-
84892852372
-
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
-
Fuchs CS, Tomasek J, Yong CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39
-
(2014)
Lancet
, vol.383
, pp. 31-39
-
-
Fuchs, C.S.1
Tomasek, J.2
Yong, C.J.3
-
8
-
-
42949149159
-
Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
-
Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019
-
(2008)
J Clin Oncol
, vol.26
, pp. 2013-2019
-
-
Saltz, L.B.1
Clarke, S.2
Diaz-Rubio, E.3
-
9
-
-
84916196944
-
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
-
Shen L, Li J, Xu J et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer 2015; 18: 168-176
-
(2015)
Gastric Cancer
, vol.18
, pp. 168-176
-
-
Shen, L.1
Li, J.2
Xu, J.3
-
10
-
-
80053573446
-
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, doubleblind, placebo-controlled phase III study
-
Ohtsu A, Shah MA, Van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, doubleblind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-3976
-
(2011)
J Clin Oncol
, vol.29
, pp. 3968-3976
-
-
Ohtsu, A.1
Shah, M.A.2
Van Cutsem, E.3
-
11
-
-
85013342415
-
Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA)
-
Enzinger PC, McCleary NJ, Zheng H et al. Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA). J Clin Oncol 2016; 34(suppl 4s): abstr 4
-
(2016)
J Clin Oncol
, vol.34
-
-
Enzinger, P.C.1
McCleary, N.J.2
Zheng, H.3
-
12
-
-
84981711242
-
CALGB 80403/ECOG 1206: A randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers
-
Enzinger PC, Burtness B, Niedzwiecki D et al. CALGB 80403/ECOG 1206: A randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. J Clin Oncol 2016; 34: 2736-2742
-
(2016)
J Clin Oncol
, vol.34
, pp. 2736-2742
-
-
Enzinger, P.C.1
Burtness, B.2
Niedzwiecki, D.3
-
13
-
-
84898430937
-
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer
-
Garcia-Carbonero R, Rivera F, Maurel J et al. An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist 2014; 19: 350-351
-
(2014)
Oncologist
, vol.19
, pp. 350-351
-
-
Garcia-Carbonero, R.1
Rivera, F.2
Maurel, J.3
-
14
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
-
Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544
-
(2007)
J Clin Oncol
, vol.25
, pp. 1539-1544
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
-
15
-
-
84942196798
-
Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer
-
Tabernero J, Ohtsu A, Muro K et al. Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer. J Clin Oncol 2015; 33(suppl 3): abstr 121
-
(2015)
J Clin Oncol
, vol.33
-
-
Tabernero, J.1
Ohtsu, A.2
Muro, K.3
-
16
-
-
84881186333
-
Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma
-
Feng Y, Roy A, Masson E et al. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 2013; 19: 3977-3986
-
(2013)
Clin Cancer Res
, vol.19
, pp. 3977-3986
-
-
Feng, Y.1
Roy, A.2
Masson, E.3
-
17
-
-
84898058380
-
Population pharmacokinetics and exposureresponse analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer
-
Cosson VF, Ng VW, Lehle M, Lum BL. Population pharmacokinetics and exposureresponse analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemother Pharmacol 2014; 73: 737-747
-
(2014)
Cancer Chemother Pharmacol
, vol.73
, pp. 737-747
-
-
Cosson, V.F.1
Ng, V.W.2
Lehle, M.3
Lum, B.L.4
-
18
-
-
84899437672
-
Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer
-
Wang J, Song P, Schrieber S et al. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. Clin Pharmacol Ther 2014; 95: 558-564
-
(2014)
Clin Pharmacol Ther
, vol.95
, pp. 558-564
-
-
Wang, J.1
Song, P.2
Schrieber, S.3
|